MetaVia announces three late-breaking abstracts accepted for ADA 2026 poster presentations

MetaVia Inc.

DA-1726 (GLP-1/glucagon dual agonist) Phase 1 Part 3 titration study data expected Q4 2026.
Vanoglipel (GPR119 agonist) preclinical combo data with resmetirom for MASH and metformin for T2D.
Presentations at ADA 2026 in New Orleans, June 5-8; posters available after event.
CEO notes DA-1726 potential as differentiated obesity treatment; vanoglipel broad liver/metabolic therapeutic potential.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.